Navigation Links
Scientists to design drug for chronic pain

Scientists at the University of Liverpool and the Royal Liverpool University Hospital have been awarded 1.4 million to design a new drug for the treatment of chronic pain.

The project funded by the Medical Research Council (MRC), addresses the long-standing and urgent need for effective therapies for chronic pain which affects around 20% of adults in Europe and the US, and more than eight million adult patients in the UK alone. Medication currently available to treat the condition is effective in only around 40% of sufferers and even these patients often struggle to maintain the balance between adequate pain relief and the adverse effects of current therapies.

The research team is examining compounds which target the glycine receptor, one of the principal inhibitory neuronal receptors in the central nervous system and crucial in the sensation of chronic pain. Through medicinal chemistry, computational methods and experimental testing, scientists successfully identified novel compounds which could be used for the treatment of chronic pain without unwanted sedative effects.

Professor Martin Leuwer, from the University's Department of Molecular and Clinical Pharmacology in the School of Translational Medicine, said: "This is an exciting project that expands our drug discovery portfolio into a new therapeutic area with a huge unmet medical need. Our collaborative team of medicinal chemists, molecular modellers and neurobiologists have made significant advances in this area and this funding provides us with the opportunity to drive the project forward towards an entirely new class of drug for the treatment of chronic pain conditions.

"We're aiming to develop molecules that target the glycine receptor, into a drug that can be administered as a tablet. Our project concept has been shown to work but further improvements are required if we are to reach the goal of generating a drug which is safe, effective and orally viable. Our ultimate aim is to allow chronic pain patients to regain a dramatically improved quality of life."

He added: "In view of the huge numbers of patients worldwide whose lives are wrecked by chronic pain, the fact that current treatment options are clearly insufficient and the dramatic toll on economies caused by millions of lost working hours, our causal treatment option has the potential to have a tremendous beneficial impact on individuals and societies."

Contact: Kate Mizen
University of Liverpool

Related medicine news :

1. Scientists from UCLA, Israels Technion uncover brains code for pronouncing vowels
2. Scientists ID Cancer-Causing Agent in Smokeless Tobacco
3. UCSB scientists examine effects of manufactured nanoparticles on soybean crops
4. Scientists report promising new direction for cognitive rehabilitation in the elderly
5. Scientists to investigate preventing life-threatening complications in transplant patients
6. Scientists decode TREX which could see new treatments for cancer realized
7. Scientists devise new strategy to destroy multiple myeloma
8. Scientists ID New Gene Regions Linked to Type 2 Diabetes
9. Scientists discover how iron levels and a faulty gene cause bowel cancer
10. Scripps Florida scientists awarded nearly $1.5 million to develop new approaches to treat cancer
11. Scientists ID New Gene Linked to Vision Loss in Infants
Post Your Comments:
(Date:6/25/2016)... ... ... closing of Bruton Memorial Library on June 21 due to a possible lice infestation, as ... of head lice: the parasite’s ability to live away from a human host, and to ... one in the event that lice have simply gotten out of control. , As lice ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of ... of the latter, setting the bar too high can result in disappointment, perhaps even ... progress toward their goal. , Research from reveals that behind ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. ... The attorneys chosen by their peers for this recognition are considered among the top ... Shareholders received special honors as members of this year’s Legal Elite Hall of Fame: ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... Calif. , June 23, 2016 Any dentist ... many challenges of the current process. Many of them do ... of the technical difficulties and high laboratory costs involved. And ... to offer it at such a high cost that the ... it. Dr. Parsa Zadeh , founder of ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
Breaking Medicine Technology: